

Amendments to the Claims:

1. (Currently amended) A recombinant Sendai virus vector comprising a gene encoding a chemokine, wherein said gene is operatively linked to a functional promoter, wherein said vector, when transfected to a host, expresses the chemokine in a biologically active form.
2. (Previously presented) The recombinant Sendai virus vector of claim 1, wherein said chemokine is CXC-chemokine.
3. (Previously presented) The recombinant Sendai virus vector of claim 2, wherein said CXC-chemokine is stromal cell-derived factor α or stromal cell-derived factor β .
4. (Original) The recombinant Sendai virus vector of claim 3, wherein said vector is disseminative.
5. (Original) The recombinant Sendai virus vector of claim 3, wherein said vector is infectious and replicates autonomously, but is not disseminative.

6. (Currently amended) A method of producing a biologically active chemokine which comprises the steps of: inserting at least one chemokine gene into a Sendai virus vector, introducing ~~said vector into a host cell~~ said vector into an isolated host cell, allowing the host to produce said chemokine, and recovering said chemokine from the culture supernatant.
7. (Previously presented) The method of claim 6, wherein said chemokine is CXC-chemokine.
8. (Previously presented) The method of claim 6, wherein said host cell expresses Sendai virus virions and the step of recovering said chemokine from the culture supernatant includes the step of removing virions by centrifugation.
9. (Canceled).
10. (Canceled).
11. (Currently amended) A ~~pharmaceutical~~ composition comprising a recombinant Sendai virus vector comprising a gene encoding a stromal cell-derived factor chemokine, wherein said gene is operatively linked to a functional promoter.

wherein said vector, ~~when transfected to a host~~ when transfected to an isolated host cell, expresses biologically active stromal cell-derived factor α or biologically active stromal cell-derived factor β and a ~~pharmaceutically acceptable~~ carrier, wherein said vector is disseminative.

12. (Currently amended) A ~~pharmaceutical~~ composition comprising a recombinant Sendai virus vector comprising a gene encoding a stromal cell-derived factor chemokine, wherein said gene is operatively linked to a functional promoter, wherein said vector, ~~when transfected to a host~~ when transfected to an isolated host cell, expresses biologically active stromal cell-derived factor α or biologically active stromal cell-derived factor β and a ~~pharmaceutically acceptable~~ carrier, wherein said vector is infectious and replicates autonomously, but it is not disseminative.

13. (Canceled).

14. (Currently amended) ~~A host cell transfected with a recombinant Sendai virus~~ An isolated host cell transfected with a recombinant Sendai virus vector expressing a biologically active chemokine.

15. (Currently amended) A method of inhibiting proliferation of HIV-infected cells *in vitro* which comprises, ~~incubating the host cell of claim 14 *in vitro*~~ incubating the isolated host cell of claim 14 *in vitro* under conditions that allow ~~for a secretion of biologically active chemokine~~ for secretion of biologically active chemokine; and contacting said chemokine with cells that are infected with HIV, wherein said chemokine inhibits proliferation of HIV-infected cells *in vitro*.
16. (Previously presented) The method of claim 7, wherein said CXC-chemokine is biologically active stromal cell-derived factor α or biologically active stromal cell-derived factor β .
17. (Previously presented) The method of claim 7, wherein said host cell expresses Sendai virus virions and the step of recovering comprises the step of removing virions by centrifugation.
18. (Previously presented) The method of claim 16, wherein said host cell expresses Sendai virus virions and the step of recovering comprises the step of removing virions by centrifugation.
19. (Canceled).

20. (Previously presented) The host of claim 14, wherein said chemokine is biologically active CXC-chemokine.
21. (Currently amended) The host of claim 20, wherein said ~~CXC-chemokine~~ biologically active stromal CXC-chemokine is biologically active stromal cell-derived factor α or biologically active stromal cell-derived factor β .
22. (Previously presented) A method of inhibiting proliferation of HIV-infected cells *in vitro* which comprises, incubating the host cell of claim 20 *in vitro* under conditions that allow for secretion of biologically active CXC-chemokine; and contacting said CXC-chemokine with cells that are infected with HIV, wherein said CXC-chemokine inhibits proliferation of HIV-infected cells *in vitro*.
23. (Previously presented) A method of inhibiting proliferation of HIV-infected cells *in vitro* which comprises, incubating the host cell of claim 21 *in vitro* under conditions that allow for secretion of biologically active CXC-chemokine; and contacting said CXC-chemokine with cells that are infected with HIV, wherein said CXC-chemokine inhibits proliferation of HIV-infected cells *in vitro*.